Condition: High-grade Squamous Intraepithelial Lesions (HSIL) · Sponsor: Shanghai BDgene Co., Ltd.
This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous intraepithelial lesions (HSIL) associated with HPV-16 infection.
This description comes directly from the study's public registry record.
Fujun Li, M.D. · 086-191 2131 1061 · fujun.li@bdgene.cn
Long Sui, M.D. · 086-138 0178 8118 · suilong@sh163.net
Always discuss trial participation with your own doctor first.
| Obstetrics & Gynecology Hospital of Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07170254